Centred at the Garvan Institute, the Australian Genomic Cancer Medicine Program provides a novel approach to treating patients with rare and uncommon cancers who have exhausted all other treatment options. Through its
In 2016, Roche launched imCORE, a global network of scientists and clinicians from leading cancer research institutions in cancer immunotherapy who will work together with scientists from Roche to accelerate the search for cures for people with cancer.
The research network is spread across 21 academic centres and nine countries, including Peter MacCallum Cancer Centre in Melbourne.
In 2016, Roche entered into an exclusive license agreement with Monash University and the Hudson Institute of Medical Research for an early-stage research collaboration, focused on proteins that stimulate anti-inflammatory pathways for the treatment of autoimmune diseases.
The collaboration aims to develop next generation treatments for autoimmune diseases, focused on proteins targeting novel molecular pathways. The partnership will enable the multi-disciplinary research team and Roche to work together to advance and translate existing and new intellectual property into novel treatments.
Investigator initiated clinical studies can play a key role in answering important medical and scientific questions about Roche's products and their appropriate application.
IIS are clinical studies initiated and managed by a non-pharmaceutical company researchers, like individual investigators, institutions, collaborative study groups or cooperative groups. The researcher is responsible for the legal and regulatory responsibilities of the trial sponsor for the conduct and management of the study as defined by all applicable laws and regulations.
Roche is recognised as one of the leaders in personalised healthcare and as a pioneer in seeking cutting edge technologies and innovative compounds that will provide the next generation of medicines to patients. Our approach to partnering is open and flexible; with a creative approach to deal structuring that is dynamic and enterprising.
Please get in contact with the Roche Australia partnering team if you are interested in discussing any of the following partnerships.
In-licensing of your existing product to complement the Roche portfolio.
Licencing or distribution of existing Roche products.
Commercial service agreements relevant to Roche research and development.
For other enquiries related to products in early-phase clinical development, contact the
Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visit